In patients with existing atherosclerotic disease or children without soluble thrombomodulin was positively associated with future CHD events and arteriosclerosis progression, which may reflect the degree of associated inflammation and endothelial damage [50,51]. This evidence concerns the gene THBD and arteriosclerosis.